FMS Stock Analysis: Buy, Sell, or Hold?
FMS - Fresenius Medical Care AG
$23.43
0.00 (0.00%)
▲
5d:
-1.43%
30d:
-4.13%
90d:
+4.13%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When FMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: FMS shows positive signals but monitor for confirmation. Market pricing in 2.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: FMS shows positive signals but monitor for confirmation. Market pricing in 2.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$42.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.61
11.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FMS is currently trading at $23.43, which is considered oversold relative to its 30-day fair value range of $23.65 to $24.84. The stock's valuation (Forward PE: 7.5) is in line with its historical norms (7.0). At these levels, the market is pricing in 2.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FMS is in a uptrend. The price is currently testing key support at $23.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FMS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $26.08 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FMS is in a uptrend. The price is currently testing key support at $23.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FMS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $26.08 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$23.65 -
$24.84
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($26.08)
- NEUTRAL: Market pricing in 2.1% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$23.65 -
$24.84
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$23.30
Resistance Level
$24.54
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.45
Wall Street Target
$26.08
(+11.3%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
5.5%
Profit Margin
4.8%
Valuation Premium vs History
+2.1% premium
PE vs Historical
7.5 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.1%
(market-implied from PE analysis)
1-Year Target
$23.92
(+2%)
2-Year Target
$24.42
(+4%)
3-Year Target
$24.94
(+6%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$23.42
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 52.1%)
$212.95
(+809%)
Base:
(SPY PE: 7.5, Growth: 52.1%)
$79.08
(+238%)
Bear:
(PE: 6.3, Growth: 52.1%)
$67.21
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 12.40 | Current EPS (TTM): $1.89
Bull Case
$42.87
(+83%)
Analyst growth 66.3%, PE expands to 13.6
Base Case
$38.97
(+66%)
Market implied 66.3%, PE stable at 12.4
Bear Case
$15.93
(-32%)
Severe decline -20.0%, PE contracts to 10.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 8:01 PM ET
Data refreshes hourly during market hours. Next update: 9:01 PM
Data refreshes hourly during market hours. Next update: 9:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$282 | 37 SELL |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$455 | 44 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$24 | 47 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 42 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$135 | 54 HOLD |
